The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria

Inflammatory Bowel Diseases

Volumn 9, Issue 1, 2003, Pages 10-17

  Edmond, Laurie M ^a   Hopkins, Mark J ^a   Magee, Elizabeth A ^a   Cummings, John H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

5 aminosalicylic acid; Amino acid fermenting bacteria; Sulfasalazine; Sulfate reducing bacteria; Sulfide; Three stage chemostat; Ulcerative colitis

Indexed keywords

AMINO ACID; BALSALAZIDE; MESALAZINE; OLSALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SULFAPYRIDINE; SULFIDE; TARTRAZINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CHEMOSTAT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG STRUCTURE; FERMENTATION; FUSOBACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; SULFATE REDUCING BACTERIUM; TIME; ULCERATIVE COLITIS;

AMINO ACIDS; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DESULFOVIBRIO; FECES; FERMENTATION; FUSOBACTERIUM; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PHENYLHYDRAZINES; SULFASALAZINE; SULFIDES;

EID: 0037242239     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200301000-00002     Document Type: Article

References (28)

1. Pitcher MCL, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
2. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
3. Roediger WEW, Duncan A, Kapaniris O, et al. Sulphide impairment of substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis. Clin Sci 1993;85:623-7.
4. Vernia P, Caprilla R, Latella G, et al. Fecal lactate and ulcerative colitis. Gastroenterology 1988;95:1564-8.
5. Wedzicha BL. Chemistry of sulphur dioxide in foods. London and New York: Elsevier Applied Science Publishers, 1984.
6. Levitt MD, Furne J, Springfield J, et al. Detoxification of hydrogen sulphide and methanethiol in the cecal mucosa. J Clin Invest 1999; 104:1107-14.
7. Magee EAM, Richardson CJ, Hughes R, et al. The contribution of dietary protein to sulphide production in the large intestine: an in vitro and controlled feeding study in human volunteers. Am J Clin Nutr 2000;72:1488-94.
8. Magee EAM, Richardson CJ, Cummings JH. The contribution of dietary protein and sulphur food additives to faecal sulphide in humans. Digestion 1998;59(suppl 3):53.
9. Bartholomew TC, Powell GM, Dodgson KS. Oxidation of sodium sulphide by rat liver, lungs and kidneys. Biochem Pharmacol 1980; 29:2431-7.
10. Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
11. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;October 27:892-5.
12. Hayllar J, Bjarnason I. Sulfasalazine in ulcerative colitis: in memoriam? Gut 1991;32:462-3.
13. Austin CA, Cann PA, Jones TH, et al. Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet 1984;i:917-8.
14. Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998;114:15-22.
15. Adhiyaman V, Vaishnavi A, Froese S. Hypersensitivity to balsalazide. BMJ 2000;320:613.
16. Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990;78:119-25.
17. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Inflammatory Bowel Dis 1997;3:65-78.
18. Richardson CJ, Magee EAM, Cummings JH. A new method for the determination of sulphide in gastrointestinal contents and whole blood by microdistillation and ion chromatography. Clin Chim Acta 2000;293:115-25.
19. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecology 1998;35:180-7.
20. Miller L, Berger T. Bacterial identification by gas chromatography of whole cell fatty acids. Hewlett-Packard Application, note 228-41. Avondale: Hewlett Packard; 1989.
21. Macfarlane GT, Gibson GR. Anaerobic microbiology: a practical approach. 1991. Oxford: Oxford University Press; Chapter 11.
22. Laursen LS, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31: 1271-6.
23. Claesson R, Edlund MB, Persson S, et al. Production of volatile sulphur compounds by various fusobacterium species. Oral Microbiol Immunol 1990;5:137-42.
24. Campieri M. Review: bacteria as a cause of ulcerative colitis. Gut 2001;48:132-5.
25. Pitcher MCL, Beatty ER, Cummings JH. The contribution of sulfate-reducing bacteria and 5-aminosalicylic acid to fecal sulphide in patients with ulcerative colitis. Gut 2000;46:64-72.
26. Roediger WEW, Duncan A. 5-Aminosalicylic acid decreases colonic sulfide formation: implications for ulcerative colitis. Medi Sci Res 1996;24;27-9.
27. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecology 1991;86:103-12.
28. Arakawa T, Ishikawa Y, Kazunari U. Volatile sulfur production by pig cecal bacteria in batch culture and screening inhibitors of sulphate reducing bacteria. J Nutr Sci Vitaminol 2000;46:193-8.